We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
11
0 active
Approvals
0
Total approvals
Agencies
Regulatory bodies
Founded
N/A
Completed
6
54.5%
Recruiting
1
9.1%
Terminated
3
27.3%
Withdrawn
No approval data available
- DelveInsight's 2025 analysis reveals over 20 key companies are developing 25+ acute ischemic stroke therapies across various clinical phases, representing significant advancement in stroke treatment research. - Recent clinical trials demonstrate promising results, including the ASSET-IT trial showing 65.9% excellent recovery rates with tirofiban combination therapy compared to 54.9% with placebo. - Multiple FDA designations have been granted, including Fast Track status for PP-007 and Orphan Drug Designation for CIRARA, accelerating development timelines for innovative stroke treatments. - The pipeline encompasses diverse therapeutic approaches including monoclonal antibodies, small molecules, and cell therapies, targeting various mechanisms from neuroprotection to thrombolysis enhancement.
